Literature DB >> 21307226

Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes.

Jean-Daniel Doucet1, Marie-Andrée Forget1, Cécile Grange1, Ronan Nicolas Rouxel2, Nathalie Arbour1, Veronika von Messling2, Réjean Lapointe1.   

Abstract

Current influenza vaccines containing primarily hypervariable haemagglutinin and neuraminidase proteins must be prepared against frequent new antigenic variants. Therefore, there is an ongoing effort to develop influenza vaccines that also elicit strong and sustained cytotoxic responses against highly conserved determinants such as the matrix (M1) protein and nucleoprotein (NP). However, their antigenic presentation properties in humans are less defined. Accordingly, we analysed MHC class I and class II presentation of endogenously processed M1 and NP in human antigen presenting cells and observed expansion of both CD8(+)- and CD4(+)-specific effector T lymphocytes secreting gamma interferon and tumour necrosis factor. Further enhancement of basal MHC-II antigenic presentation did not improve CD4(+) or CD8(+) T-cell quality based on cytokine production upon challenge, suggesting that endogenous M1 and NP MHC-II presentation is sufficient. These new insights about T-lymphocyte expansion following endogenous M1 and NP MHC-I and -II presentation will be important to design complementary heterosubtypic vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307226     DOI: 10.1099/vir.0.029777-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

Review 1.  The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.

Authors:  Asha Purnima Veerappan Ganesan; Laurence C Eisenlohr
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

2.  4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Authors:  Donastas Sakellariou-Thompson; Marie-Andrée Forget; Caitlin Creasy; Vincent Bernard; Li Zhao; Young Uk Kim; Mark W Hurd; Naohiro Uraoka; Edwin Roger Parra; Ya'an Kang; Christopher A Bristow; Jaime Rodriguez-Canales; Jason B Fleming; Gauri Varadhachary; Milind Javle; Michael J Overman; Hector A Alvarez; Timothy P Heffernan; Jianhua Zhang; Patrick Hwu; Anirban Maitra; Cara Haymaker; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 12.531

Review 3.  Influenza vaccination in the elderly.

Authors:  Jan Smetana; Roman Chlibek; Jana Shaw; Miroslav Splino; Roman Prymula
Journal:  Hum Vaccin Immunother       Date:  2017-08-04       Impact factor: 3.452

4.  Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Authors:  René J Tavera; Marie-Andrée Forget; Young Uk Kim; Donastas Sakellariou-Thompson; Caitlin A Creasy; Ankit Bhatta; Orenthial J Fulbright; Renjith Ramachandran; Shawne T Thorsen; Esteban Flores; Arely Wahl; Audrey M Gonzalez; Christopher Toth; Seth Wardell; Rahmatu Mansaray; Laszlo G Radvanyi; Dan S Gombos; Sapna P Patel; Patrick Hwu; Rodabe N Amaria; Chantale Bernatchez; Cara Haymaker
Journal:  J Immunother       Date:  2018 Nov/Dec       Impact factor: 4.456

Review 5.  Vaccine strategies to enhance immune responses in the aged.

Authors:  Julie S Lefebvre; Laura Haynes
Journal:  Curr Opin Immunol       Date:  2013-06-10       Impact factor: 7.486

6.  Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.

Authors:  Freek Cox; Matthijs Baart; Jeroen Huizingh; Jeroen Tolboom; Liesbeth Dekking; Jaap Goudsmit; Eirikur Saeland; Katarina Radošević
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

7.  Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Ann L Oberg; Michael T Zimmermann; Diane E Grill; Gregory A Poland
Journal:  Front Immunol       Date:  2016-11-02       Impact factor: 7.561

Review 8.  Targeting Antigens for Universal Influenza Vaccine Development.

Authors:  Quyen-Thi Nguyen; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

Review 9.  Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.

Authors:  Shahzma Merani; Graham Pawelec; George A Kuchel; Janet E McElhaney
Journal:  Front Immunol       Date:  2017-07-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.